Gastrointestinal Symptoms and the Mediterranean Dietary Pattern: Secondary Analysis of a Randomized Controlled Trial in a Population with Increased Cardiometabolic Risk

Why It Matters

The findings demonstrate that a Mediterranean‑style diet can safely improve gut comfort and quality of life in at‑risk populations, reinforcing its role as a comprehensive lifestyle prescription for cardiometabolic health.

Key Takeaways

• NZMedDiet lowered abdominal pain scores by 0.27 (p=0.01).
• All GSRS domains showed modest but significant reductions.
• Women and Māori reported higher baseline GI symptoms.
• Symptom improvements linked to better SF‑36 quality‑of‑life scores.
• Intervention provided ~75% of daily calories, boosting adherence.

Pulse Analysis

Gastrointestinal discomfort is a pervasive, often under‑diagnosed issue that can erode quality of life even in individuals without a formal gut disorder. While Western dietary patterns exacerbate these symptoms, the Mediterranean diet—rich in fiber, plant foods, and healthy fats—has been linked to both cardiometabolic protection and gut health. Yet evidence has been limited to clinical populations such as IBS patients. This New Zealand secondary analysis fills a gap by evaluating the diet’s impact on a broader, cardiometabolic‑risk cohort, highlighting the relevance of dietary strategy beyond disease‑specific settings.

The trial enrolled 200 adults (average age 50, 62% female) and delivered roughly three‑quarters of their daily calories as Mediterranean‑aligned foods for twelve weeks. Compared with a control group, participants on the NZMedDiet experienced statistically significant reductions in all five GSRS domains, most notably abdominal pain (‑0.27 points). Baseline analyses revealed that women and Māori participants bore a higher symptom burden, underscoring the importance of culturally tailored nutrition interventions. Correlation analyses showed that each decrement in GI symptom scores was associated with modest gains in SF‑36 quality‑of‑life domains, particularly general health and social functioning.

These results suggest that Mediterranean‑style eating can be a tolerable, multi‑benefit approach for individuals at cardiometabolic risk, delivering incremental gut‑symptom relief alongside established metabolic advantages. The modest effect sizes likely reflect low baseline symptom severity, but they still signal a clinically relevant trend, especially for sub‑populations with higher symptom loads. Mechanistically, the diet’s fiber‑driven short‑chain fatty acid production, anti‑inflammatory polyphenols, and favorable microbiome shifts may underlie the observed benefits. Future research should target larger, more diverse cohorts, explore long‑term adherence without food provision, and define minimum clinically important differences for GI outcomes in preventive nutrition trials.